SMi Group's 5th ADC Summit to highlight developments for next wave of antibody-drug conjugates
SMi Group reports (2016.21.01): The 5th annual ADC Summit takes place at the Holiday Inn Kensington Forum, London, UK on the 23rd – 24th May 2016
LONDON -

SMi's 5th ADC Summit provides a comprehensive analysis of the various approaches with the next generation ADCs. Hear the latest insights from Takeda on Adcetris; discuss the latest advancements in research and development from Medimmune; and analyse case studies from big pharma companies such as Roche, Bayer, Pfizer, AstraZeneca, Novartis and many more.
Key sessions include:
• Takeda presents how ADCETRIS® (brentuximab vedotin) was developed to treat Hodgkin Lymphoma
• Advancement in antibody drug conjugates: a step closer to magic bullets in war against cancer
• Safety at the forefront: homogeneity of ADCs for highly effective and safer cancer therapy and many more.
For the the complete event agenda including all speakers and their topics, visit http://www.adcsummit.com/ein
In addition, don’t miss the two interactive half-day post-conference workshops taking place on the 25th May 2016 at the Holiday Inn Kensington Forum, London:
WORKSHOP A: ADC Payloads: Availability and Mechanisms of Action hosted by Femtogenix and King's College London
WORKSHOP B: Developments in High Potency Manufacturing hosted by SKAN AG
Join industry experts as they share, confer and debate how to create the next wave of ADCs with better efficacy, lower toxicity and improved potency for clinical success.
Book by February 29th to benefit from the £400 early bird discount.
For more information or to register visit http://www.adcsummit.com/ein
About SMi Group:
Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102